Why is the Incannex share price spiking 8% on Tuesday?

The stock has caught a bid on Tuesday.

| More on:
A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex shares have lifted today following the release of a company presentation
  • In it the company gave an in depth view of its assets and operations, including the value proposition at hand
  • In the last 12 months the Incannex share price has clipped a 5% gain

The Incannex Healthcare Ltd (ASX: IHL) share price has jumped from the opening gate on Tuesday.

At the time of writing, Incannex was trading nearly 8% higher at 28 cents a share following the release of a company presentation.

It's a welcome gain for the medicinal cannabis company which has seen its share price plunge 55% over the past few months.

The chart below shows the Incannex share price plotted against the S&P/ASX 200 Index (ASX: XJO) for the past 12 months of trading.

TradingView Chart

What did Incannex release?

The company posted an overview of its assets, operations, and unique value proposition in the presentation released today.

Incannex described its intellectual property's "six categories of opportunity".

The company said it covers a potential $290 billion addressable market estimate for its lead drug candidates and $2 billion per year in potential revenue from psychedelic treatment therapies.

One of Incannex's lead drug candidates is IHL-42X, indicated in the treatment of obstructive sleep apnoea (OSA).

The OSA devices market is valued at US$10 billion, Incannex said, and it's projected to grow at 6.2% annually.

The drug candidate has made inroads in providing a novel solution to OSA, with data from clinical trials holding up well from a safety and efficacy standpoint.

So much so, the patent application for the drug "was considered 'novel and inventive' by [the] international patent examiner", Incannex said.

Incannex also noted it had a cash position of $37.5 million as of 30 June 2022 after raising $24 million in an equity raising in Mary 2022.

Those shares were issued at 35 cents a piece, a decent notch above the company's current share price.

The Incannex share price has clipped a 4% gain these past 12 months.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »